# US 7,608,684 B2 · Soluble CD14 antigen > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,608,684 B2 - Document ID: US7608684B2 - Status: Granted - Kind: B2 - Application number: 11/126,344 - Filed: 2005-05-11 - Published: 2006-03-30 - Granted: 2009-10-27 - Earliest claimed: 2002-11-12 - Assignees: Mochida Pharmaceuticals Co., Ltd. - Inventors: Shoji Furusako; Kamon Shirakawa; Jiro Hirose - Web page: https://patentgrep.com/patent/US7608684B2 ## CPC - C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere} - C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere} - G01N 33/6893: {related to diseases not provided for elsewhere} - C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues - G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705 - G01N 2800/26: Infectious diseases, e.g. generalised sepsis - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract There are provided a soluble CD14 antigen which is a novel in vivo protein useful as a marker for diagnosing sepsis and has the following characteristic features 1) to 3): 1) a molecular weight of 13±2 kDa when measured by SDS-PAGE under non-reducing conditions; 2) an amino acid sequence in which the amino acid sequence of SEQ ID NO:1 is present on its N terminal; and 3) ability to specifically bind to an antibody prepared by using a peptide comprising 16 amino acid residues described in SEQ ID NO:2 for the antigen; and a recombinant soluble CD14 fragment. ## Claims ### Claim 1 An isolated soluble CD14 antigen, which consists of the amino acid sequence from position 1 to any one of positions 59 to 90 of the amino acid sequence of SEQ ID NO:3, wherein said soluble CD14 antigen has no ability to specifically bind to 3C10 antibody, ATCC No. TIB-228 and no ability to bind to LPS, and wherein said isolated soluble CD14 antigen has a molecular weight of 13±2 kDa when measured b SDS-PAGE under non-reducing conditions. ### Claim 2 (depends on 1) The soluble CD14 antigen according to claim 1, wherein said soluble CD14 antigen is capable of being obtained from human plasma serum. ### Claim 3 (depends on 1) The soluble CD14 antigen according to claim 1, wherein said soluble CD14 antigen specifically binds to an antibody, which binds a peptide consisting of the amino acid sequence of SEQ ID NO :2. ### Claim 4 (depends on 1) The soluble CD14 antigen according to claim 1, wherein said soluble CD14 antigen has no ability to specifically bind to MEM-18 antibody. ### Claim 5 (depends on 1) The soluble CD14 antigen according to claim 1, wherein said soluble CD14 antigen is capable of being obtained from human serum; has a molecular weight of 13±2 kDa when measured by SDS-PAGE under non-reducing conditions, has no ability to specifically bind to MEM-18 antibody; and specifically binds to an antibody which binds a peptide consisting of the amino acid sequence of SEQ ID NO:2. ### Claim 6 An isolated soluble CD14 antigen, which consists of the amino acid sequence from any one of positions 1 to 6 to any one of positions 59 to 90 of the amino acid sequence of SEQ ID NO:3, wherein said soluble CD14 antigen is capable of being obtained from human serum; has no ability to specifically bind to 3C10 antibody, ATCC No. TIB-228; has no ability to bind to LPS has a molecular weight of 13±2 kDa when measured by SDS-PAGE under non-reducing conditions, has no ability to specifically bind to MEM-18 antibody; and specifically binds to an antibody which binds a peptide consisting of the amino acid sequence of SEQ ID NO:2. ### Claim 7 An isolated recombinant soluble CD14 fragment, which consists of the amino acid sequence from any one of positions 1 to 17 to any one of positions 59 to 90 of the amino acid sequence of SEQ ID NO:3; wherein said recombinant soluble CD14 fragment has no ability to specifically bind to 3C10 antibody, ATCC No. TIB-228 and MEM-18 antibody, and no ability of binding to LPS, and wherein said recombinant soluble CD14 fragment has a molecular weight of 13±2 kDa when measured by SDS-PAGE under non-reducing conditions. ### Claim 8 (depends on 7) The isolated recombinant soluble CD14 fragment according to claim 7, wherein said recombinant soluble CD14 fragment specifically binds to an antibody which binds a peptide consisting of the amino acid sequence of SEQ ID NO:2. ### Claim 9 (depends on 7) The isolated recombinant soluble CD14 fragment according to claim 7, wherein the N terminus of said recombinant soluble CD14 fragment is any one of positions 1 to 6 of the amino acid sequence of SEQ ID NO:3. ### Claim 10 (depends on 9) The isolated recombinant soluble CD14 fragment according to claim 9, wherein the N terminus is position 1. ### Claim 11 (depends on 7) The isolated recombinant soluble CD14 fragment according to claim 7, wlierein the C terminus of said recombinant soluble CD14 fragment is any one of positions 64 to 75 of the amino acid sequence of SEQ ID NO:3. ### Claim 12 (depends on 7) The isolated recombinant soluble CD14 fragment according to claim 7, wherein said recombinant soluble CD14 fragment has a molecular weight of 13±2 kDa when measured by SDS-PAGE under non-reducing conditions, specifically binds to an antibody which binds a peptide consisting of amino acid sequence of SEQ ID NO:2, has an N tenninus that is position 1 of the amino acid sequence of SEQ ID NO:3; and has a C terminus is that is any one of positions 64 to 75 of the amino acid sequence of SEQ ID NO:3.